News

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
Eli Lilly Vs. Novo Nordisk: Which Pharma Stock Is Likely to Do Better in 2025?
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study
Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...
Novo Nordisk Tumbles as Lilly's Zepbound Shows Greater Weight Loss in Trial
Novo Nordisk shares dropped 5% in early trading on Monday after Eli Lilly released new trial data showing its weight loss ...
STAT17h
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Money Morning10h
Eli Lilly (LLY): Should You Buy or Sell After Drug Price Order?
Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...
Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial
Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...
Jim Cramer on Eli Lilly and Company (LLY) – “Buy Hand Over Fist – This GLP-1 Giant Just Crushed Novo”
We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at ...